CISI FIN (06058.HK): Discloseable Transaction — Subsidiary Disposes of USD 20.15 Million Notes, Recording a Gain of About USD 165,407
- The notes were issued by Joy Treasure Assets Holdings Inc. and guaranteed by China Orient Asset Management (International) Holding Limited, with a maturity date of 4 December 2028 and a fixed annual interest rate of 4.30%.
- The Group recorded a gain of approximately USD 165,407 (equivalent to approximately HKD 1,298,444), with the proceeds to be used as general working capital of the Group.
- As one of the applicable percentage ratios on an aggregated basis with the previous disposals exceeds 5% but is below 25%, the disposal constitutes a discloseable transaction exempt from shareholders' approval.
NewTimeSpace News: On 18 September 2026, China Industrial Securities International Financial Group Limited (stock code: 06058) announced that between 15 June 2026 and 17 September 2026, CISI Investment Limited, an indirectly wholly-owned subsidiary of the Company, disposed of notes with an aggregate principal amount of USD 20,150,000 (equivalent to approximately HKD 158,177,500) in the open market at a total consideration of approximately USD 20,080,767 (equivalent to approximately HKD 157,634,020).
The notes were issued by Joy Treasure Assets Holdings Inc. and unconditionally and irrevocably guaranteed by China Orient Asset Management (International) Holding Limited, with a maturity date of 4 December 2028 and a fixed annual interest rate of 4.30%. The disposal was conducted in the open market at prevailing market prices, and the Group recorded a gain of approximately USD 165,407 (equivalent to approximately HKD 1,298,444), with the proceeds of approximately USD 20,080,767 to be used as general working capital of the Group. As one of the applicable percentage ratios on an aggregated basis with the previous disposals exceeds 5% but is below 25%, the disposal constitutes a discloseable transaction subject to the reporting and announcement requirements but exempt from shareholders' approval.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CISI FIN(06058.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 137.75 million, YoY increase of 33.82%
- MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect
- Micot (02335.HK): Phase‑II Clinical Trial of MT200605 for Acute Ischemic Stroke Completed, AKI Incidence Reduced by Over 80% in High‑dose Cohort
- MICOT PHARMA-B (02335.HK): To Be Included as Hang Seng Composite Index Constituent with Effect from 7 September
- MICOT PHARMA-B (02335.HK): Three XTL6001 Studies Accepted for Presentation at EASD 2026 and ASN Kidney Week 2026, Triple-Agonist Mechanism Gains International Recognition